Your Name Is on the Door. A Buyer Calls That Risk.

The tour

Picture a composite tour. The acquisitions director arrives at ten. The practice is, by any standard, impressive — and it is impressively named. The founder’s name is etched on the door, set in brass at reception, repeated across the website, the letterhead, the consent forms, the signature results gallery, the Google listing with its hundreds of reviews. The practice manager, showing her round, is proud of all of it, and says the thing practice managers say on these tours: patients come here for him. They wait months. They fly in.

Watch the visitor’s face, because two things are happening on it at once. Admiration, which is genuine — the reputation took twenty years of skill to build and she knows exactly what that costs. And, underneath it, a quiet recalculation. Every compliment the tour produces raises her regard for the founder and lowers her confidence in the purchase. Patients come here for him is, to her ear, a sentence with a second clause the practice manager has not said aloud: and might not come here for anyone else.

By the end of the corridor she has not seen a practice. She has seen a person, magnificently housed. The distinction will be worth a great deal of money to somebody, and the founder should want it to be him.

The founder paradox

Here is the paradox this article exists to take seriously, because it deserves better than a slogan. The strongest personal reputation in a catchment can produce the weakest transfer in it. Not because the reputation is hollow — precisely because it is real. Demand that terminates in one person is real demand and untransferable demand at the same time, and the more completely the founder’s name explains the practice’s success, the less of that success a buyer can safely believe she is buying.

None of this is an argument against the name. The name built the thing. Eminence creates referrals, referrals create case flow, case flow creates the earnings everyone is now discussing. History is kind to eponymous empires; it is also quietly littered with distinguished practices that turned out, at the point of transfer, to be one remarkable person with a lease. The task is not to erase the founder, dilute the reputation or retreat into beige institutional anonymity. The task is a conversion: turning personal authority into assets the business can hold and demonstrate — and doing it while the authority is at its height, which is exactly the moment it feels least necessary.

Two kinds of goodwill

The valuation profession has a vocabulary for this, and it is worth borrowing because it is the vocabulary the other side of the table will be using.

For the purposes of founder dependence, the valuation literature offers one especially useful distinction within goodwill: personal or professional goodwill, and enterprise goodwill. Professional goodwill is earning power attached to an individual: her skill, her reputation, her relationships, the demand that follows her specifically. Enterprise goodwill is value that belongs to the business itself — systems, brand, team capability, patient pathways, referral architecture.¹ The distinction sounds academic until you notice what turns on it. Enterprise goodwill is more likely to survive a change of ownership. Personal goodwill is less readily transferable and often depends upon the founder remaining involved long enough for patients, referrers and authority to migrate; it may still contribute to a transaction, but it is harder to transfer cleanly and commonly requires continued founder involvement, transition arrangements or contractual protections. The valuation literature’s classic image is the heart surgeon, who can sell her practice but cannot sell her hands.² Where a practice’s value is mostly personal, buyers may respond through a lower upfront price, deferred consideration, a longer transition or contractual protections appropriate to the jurisdiction.³

Most founder-led practices have never asked which kind of goodwill they have been building. The honest answer, for the eminent surgeon and the name-above-the-door principal, is often weighted heavily towards the personal kind — by accident, over twenty years. The good news is that the conversion is not mysterious. It has a name.

What quiet IP actually is

The book behind this series includes an interlude by Olivia Dhordain, an intellectual-property lawyer of the Paris and Geneva bars whose career has been spent in luxury — watchmakers, jewellers, maisons — and who read a book about dental and surgical practices and recognised her own clients immediately. Her distinction is the useful one. Every business has its loud rights: the trademark, the name, the logo, the registered design. But behind the loud rights sits what she calls quiet IP — and quiet IP is where founder authority becomes transferable.⁴

Quiet IP is know-how made visible. The documented diagnostic protocol. The signature patient pathway written down step by step rather than performed from memory. The consultation framework a coordinator can be trained on. The training system that turns a good hire into a practice-standard clinician. The membership and recall architecture. The clinical articles and patient education that fix professional judgement in a form the business can keep using. Referral relationships maintained by more than one person, documented through the practice and capable of surviving the founder’s reduced involvement. Even the documented record of what not to do — negative knowledge, hard-won — which buyers almost never find written down.

Some of this, properly handled, acquires legal character: the particular expression of expertise may carry copyright; genuinely confidential, documented and restricted know-how may amount to trade secrets; the name and marks can be registered. But precision matters here, and this article is not legal advice. Copyright protects the particular expression of expertise, not the underlying clinical idea or method itself. Separate questions of confidentiality, contract, patentability and professional regulation may still arise; documenting a protocol does not, by itself, make the underlying method proprietary. And for each asset the practice should be able to demonstrate ownership, contractual rights, controlled access or operational continuity, as appropriate.⁴ None of this is exotic. The UK Intellectual Property Office’s knowledge-asset guidance describes exactly this class of asset — documented processes, data, systems, know-how, and the relationships and reputation an organisation builds — and notes that much of it is protected through confidentiality and contract rather than registration; Australian guidance treats trade-secret protection the same way, as a discipline of identification and confidence before it is ever a legal remedy.⁵ The order of operations is the point. First make the value visible inside the business — identified, documented, access-controlled and attributable; it need not become public to become measurable. Then involve the right advisers before disclosure, publication or transfer makes protection harder. The lawyers do not invent the asset, but they should arrive before the asset escapes.

Visible founder, transferable practice

The fear, at this point in the argument, is always the same: that institutionalising the practice means neutering it. If the protocols are documented and the associates are credible, what happens to the thing that made the practice exceptional — the founder’s taste, judgement, standards, presence?

The fear mistakes what is actually being transferred. The founder does not become less visible under this discipline; she becomes differently load-bearing. She remains the practice’s public authority — the author of its philosophy, the standard-setter, the name on the papers and the podium — while ceasing to be its single point of delivery. In practical terms the moves are unglamorous. The signature service line is separated into what can responsibly be documented — patient-selection principles, consultation architecture, peri-operative pathway, standards, follow-up and outcome review — while any second clinician remains independently credentialled and exercises independent clinical judgement, with the founder’s endorsement doing publicly what her presence used to do privately. The practice publishes authority under more than one name, so that the brand accumulates credibility rather than merely borrowing the founder’s. Referrers are introduced, deliberately and early, to the colleagues who will treat their patients well after the founder cuts her clinical days. The consultation experience — tone, thoroughness, follow-up — is written into scripts and training rather than left to atmospheric osmosis. And the brand itself is examined honestly: is it distinguishable from the founder’s biography, or is the website essentially a CV with a booking form?

Done over years rather than months, and done well, none of this need read to patients as dilution. It can read as depth. The practices that manage it stop being one person with an audience and become an institution with a distinguished founder — which is, not coincidentally, a version a buyer can believe in with materially greater confidence.

What the buyer tests

When the examination comes, it is concrete. The buyer’s first serious question, asked early, is what proportion of fee income the founder personally generates and what happens to it the Monday she stops. The book behind this series uses two working diagnostic markers here: above forty per cent of private fee income generated personally by the founder is treated as a warning light; below twenty-five per cent is treated as a strategic target for greater transferability. They are not market cut-offs or valuation rules. They are deliberately severe management heuristics, and they exist to make the buyer’s question answerable before she asks it.⁶

The second thing she tests is verifiability. Experienced practice buyers and advisers return repeatedly to the same test: can the claims made during the tour be verified quickly, consistently and without relying on the founder’s assurances?⁶ The internal story of the practice and the externally verifiable story are different documents, and the price is paid against the second. Reputation, on this test, is not evidence. Documented pathways are evidence. Associate contracts are evidence. Referral records, published authority under multiple names, a transition plan in writing, a team that can explain the clinical philosophy without the founder in the room — evidence, all of it. What the book calls believability is the commercial quality being priced: not the founder’s excellence alone, but the practice’s ability to demonstrate that its standards, demand and operating capability survive her.

Which invites the diagnostic. Ten questions — the ones the tour is silently asking. Answer them honestly and you have the buyer’s view of your name.

The Reputation Transfer Test

1. What proportion of new patients explicitly request the founder, and what happens to those enquiries when she is unavailable?
2. What proportion of revenue requires the founder’s personal clinical delivery?
3. Could an associate or colleague explain the practice’s clinical philosophy, unprompted, to a stranger?
4. Are the signature patient pathways documented — or performed from memory?
5. Does the practice publish authority under more than one name?
6. Would your referrers keep referring if the founder halved her clinical days next quarter — and how do you know?
7. Can the team hold the practice’s tone, standards and follow-up without improvisation?
8. Is the brand distinguishable from the founder’s biography?
9. What knowledge about how this practice actually works currently lives only in one person’s memory?
10. What, specifically, would disappear on Monday if the founder did not return?

There is no score. The length and comfort of the answers is the score. A founder who can answer the tenth question with a short list has quiet IP; a founder who answers it with a silence has a reputation — a magnificent one, entirely hers, and priced accordingly.

The succession dividend

The final thing worth saying is that this work pays out whether or not the buyer ever arrives, because everything on the list above is also the machinery of choice. The founder with documented pathways and credible colleagues may be able to reduce her clinical days without a proportionate reduction in the practice’s output. She can take a partner, or admit the next generation, on terms that reflect an institution rather than a dependency. She can keep operating on the cases only she should do, at the top of her powers, while the practice carries the rest. She can, when the time comes, be succeeded rather than merely replaced — and there is a difference, visible in what the place feels like five years later. Or she can sell, well, to a buyer whose tour produces admiration and confidence in the same breath.

The Exit Discipline, published in 2026, treats this conversion across its chapters on quiet IP, leadership without heroics, and the buyer’s examination that tests whether any of it is real. Readers who want to begin with the mirror rather than the method can read more about the book or download the opening chapter.

The name on the door is not the problem. It never was. The problem is a name that has been asked to hold, in one person’s working life, value that belongs in the business — and the correction, unlike reputation, can be built on purpose.

Gregory William Gray is the author of The Exit Discipline (Summit Communication Group, 2026). He has spent more than twenty years working alongside owner-led private dental and plastic-surgical practices in the United Kingdom and Australia.

Source notes

1. The professional/personal versus enterprise/institutional goodwill distinction as set out in the recognised valuation literature: Shannon P. Pratt on the allocation between professional (personal) and institutional (practice) goodwill, and standard treatments defining enterprise goodwill as value that exists regardless of who owns or operates the business and is therefore transferable on sale (e.g. Stout, “Identification, Documentation, and Valuation of Personal Goodwill”, 2022). ↩
2. Gary R. Trugman, Understanding Business Valuation, 5th edition (AICPA, 2017): professional practices’ value depends heavily on the skills, reputation and efforts of individual professionals, part of which may not be transferable — the heart-surgeon image paraphrased in-text. Accessed via Merrimack Business Appraisers’ published summary of the literature. ↩
3. Adviser commentary on how buyers manage residual personal goodwill in practice transactions — transition periods, earn-outs, employment agreements and restrictive covenants (e.g. Brady Ware, “Goodwill: Understanding the Two Types”; Windes, “Valuing Goodwill”, 2025). United States adviser commentary; the mechanisms described are general deal architecture, not tax or legal advice in any jurisdiction. ↩
4. Olivia Dhordain, “The Quiet IP in the Practice”, interlude in The Exit Discipline (2026): loud rights versus quiet IP; know-how, documented protocols, training systems and confidential material as potential copyright or trade-secret subject matter, with the stated caveats that copyright protects expression rather than underlying clinical knowledge and that documentation, restriction and demonstrable business ownership precede legal protection. Dhordain is founder of Outboxing IP and an avocat of the Paris and Geneva bars. ↩ ↩
5. UK Intellectual Property Office, Knowledge Asset Management guidance (GOV.UK, 2026): knowledge assets include documented processes, data, systems, IP, and the relationships and reputation an organisation builds, with data, know-how and expertise protected through confidentiality, non-disclosure agreements or contractual terms. Australian position on trade secrets — protection grounded in confidence and contract rather than a registration regime — per standard Australian guidance and current practice commentary (e.g. Chambers Trade Secrets 2026, Australia). ↩
6. Gregory William Gray, The Exit Discipline (2026), Chapters Eleven and Thirteen: the forty per cent / twenty-five per cent diagnostic markers (deliberately severe management heuristics, cited as such and not as market cut-offs); believability as the commercial quality a buyer prices; and the verifiability test as articulated in the book’s examination chapter. Authorial doctrine and observation, cited as such. ↩ ↩

Nothing in this article is legal, tax or valuation advice. Goodwill classification, intellectual-property protection and deal structure are jurisdiction-specific and belong with the practice’s own advisers.